Varian Medical Systems reported fairly weak fiscal fourth-quarter results. The company’s performance continues to be affected by tightening U.S. radiology reimbursement for freestanding clinics and the generally weak hospital spending environment. Our narrow moat and positive moat trend ratings remain intact; we continue to believe Varian is well positioned to capitalize on its strong technological…
Although Dentsply’s revenue growth continues to fall slightly short our expectations, management’s ability to offset the medical device tax combined with the integration of Astra Tech kept total earnings growth near analyst’s forecasts. Excluding precious metals, Dentsply’s revenue increased 3.4%, or 2.7% on a constant currency basis, which is slightly below last year’s internal growth…
Polaris continues to deliver better-than-expected results, benefiting from persistent demand in response to well-received product launches and healthy growth in recently acquired businesses. While our narrow moat is predicated on strength in the firm’s brand and traditional product categories, we believe acquisitions and expansion into adjacent businesses could act as a major catalyst for earnings…
Banco Bradesco reported net income of BRL 3 billion (about $1.4 billion) for the third quarter. This was a 3.5% increase sequentially and 6.5% on a year-over-year basis. We are maintaining our narrow-moat rating and our fundamental outlook for the company at this time. Net interest income was BRL 11.7 billion, up 17% sequentially from…
Quest Diagnostics followed up its earlier release of disappointing preliminary third-quarter results with more details behind the under performance and pulled back its outlook for the full year. The addition of this information has not materially changed our assumptions and we are holding steady on our $65 fair value estimate. Despite the new management team’s…
